Aurdan Capital Management LLC Sells 1,130 Shares of Medtronic PLC $MDT

Aurdan Capital Management LLC cut its stake in shares of Medtronic PLC (NYSE:MDT) by 4.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 23,390 shares of the medical technology company’s stock after selling 1,130 shares during the quarter. Aurdan Capital Management LLC’s holdings in Medtronic were worth $2,039,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. 1248 Management LLC bought a new position in Medtronic in the 1st quarter valued at $26,000. Columbia River Financial Group LLC bought a new position in Medtronic in the 1st quarter valued at $28,000. Twin Tree Management LP bought a new position in Medtronic in the 1st quarter valued at $29,000. Activest Wealth Management raised its position in Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after purchasing an additional 322 shares during the last quarter. Finally, Hughes Financial Services LLC bought a new position in Medtronic in the 1st quarter valued at $32,000. Institutional investors own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MDT. Citigroup lifted their price objective on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research report on Tuesday, October 7th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $111.00 price objective on shares of Medtronic in a research report on Friday, October 10th. Stifel Nicolaus lifted their price objective on Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research report on Thursday, October 9th. Morgan Stanley restated an “overweight” rating and set a $107.00 target price (up previously from $98.00) on shares of Medtronic in a research report on Tuesday, July 15th. Finally, BTIG Research restated a “neutral” rating on shares of Medtronic in a research report on Friday, July 11th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $102.82.

Medtronic Price Performance

Shares of MDT stock opened at $90.82 on Friday. The stock has a 50-day moving average price of $94.35 and a 200 day moving average price of $89.72. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The firm has a market cap of $116.49 billion, a price-to-earnings ratio of 25.02, a PEG ratio of 2.42 and a beta of 0.78. Medtronic PLC has a 12 month low of $79.29 and a 12 month high of $99.37.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.03. The firm had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company’s revenue was up 7.7% on a year-over-year basis. During the same period last year, the company earned $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Research analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 17th. Investors of record on Friday, September 26th were issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date was Friday, September 26th. Medtronic’s dividend payout ratio is currently 78.24%.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the sale, the executive vice president owned 35,615 shares in the company, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director William R. Jellison acquired 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average price of $92.37 per share, with a total value of $230,925.00. Following the acquisition, the director directly owned 5,000 shares of the company’s stock, valued at $461,850. The trade was a 100.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.